Utah Medical Products Reports Q2 Decline

Utah Medical Products (UTMD) reported a Q2 2025 revenue decline of 4.3% to $9.95 million and an 11.7% drop in net income to $3.05 million, primarily driven by an anticipated reduction in sales to its key biopharma customer, PendoTECH, and broad weakness in international distribution. Gross profit margins contracted by 3.9 percentage points to 56.2% amid higher costs and an unfavorable product mix in Irish operations. Despite these headwinds, domestic direct sales showed resilience, and the company reduced operating expenses, largely through lower litigation costs, while maintaining a strong balance sheet and returning capital to shareholders. Management reaffirmed full-year non-GAAP EBITDA guidance, but investors should monitor international sales trends and ongoing margin pressures, particularly from Irish operations.

Analysis

Utah Medical Products (UTMD) reported second-quarter 2025 results that aligned with management's tempered expectations, characterized by a strategic revenue decline and significant margin pressure. GAAP revenue fell 4.3% year-over-year to $9.95 million, a drop largely attributable to the anticipated 38% reduction in domestic OEM sales following the loss of business from its major customer, PendoTECH, which accounted for 71% of the total revenue decline. This headline weakness masks a resilient core domestic business, where direct sales grew 10% and Filshie Clip System sales rose 8%. However, the company faces substantial headwinds internationally, with sales declining 11.6% in the first half and a concerning 21.4% in constant currency terms for the quarter, signaling fundamental weakness beyond foreign exchange effects. Gross profit margin contracted sharply by 390 basis points to 56.2%, its lowest in several years, driven by an unfavorable product mix and higher costs at its Irish manufacturing facility. While the company demonstrated effective cost control by reducing operating expenses, primarily through a $355,000 decrease in litigation costs, net income still fell 11.7% to $3.05 million. The firm's financial position remains robust with $82.2 million in cash and no debt, enabling continued capital returns through an increased dividend and $6.7 million in share repurchases in the first half, which partially supported the $0.94 EPS.

Key Decisions for Investors

• Investors should assess whether the 10% growth in domestic direct sales can scale sufficiently to compensate for the structural loss of OEM revenue and the severe, double-digit declines in the international segment.
• Monitor gross margin trends closely, as the sharp contraction to 56.2% originating from Irish operations represents a critical risk to profitability that could persist if product mix and cost issues are not resolved.
• Consider the strong debt-free balance sheet and active capital return program as a defensive cushion, but weigh this against the operational challenges and the reaffirmed yet uninspiring guidance for $17–$18 million in non-GAAP EBITDA.